Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Am J Health Syst Pharm ; 81(2): 61-65, 2024 Jan 05.
Article in English | MEDLINE | ID: mdl-37773728

ABSTRACT

PURPOSE: Biosimilar tumor necrosis factor inhibitors (b-TNFi) reduce healthcare costs and maintain equal efficacy when compared to their originator counterparts (o-TNFi). Current practice is to start patients on a slower standard infusion rate during the initial transition from an o-TNFi to a b-TNFi. There is a knowledge gap around switching from rapid originator infusion to rapid biosimilar infusion in the pediatric inflammatory bowel disease (IBD) population. SUMMARY: We present a case series of 8 pediatric patients with IBD who were switched from a rapid-infusion o-TNFi to a rapid-infusion b-TNFi from 2016 through 2022. Our primary interest was safety, which we evaluated based on the occurrence of infusion reactions or need for new premedications within the first 6 months of starting a b-TNFi. We also examined effectiveness through the incidence of IBD-related hospitalizations, TNFi failure, and need for co-medication or dose escalation over the same period. In our cohort, 4 patients had Crohn's disease and 4 had ulcerative colitis. All patients were switched to a biosimilar for nonmedical reasons. During the follow-up period, no patients had infusion reactions necessitating new premedications, serious adverse events, or medication nonresponse. CONCLUSION: Patients who directly transitioned from a rapid-infusion o-TNFi to a rapid-infusion b-TNFi did not experience serious adverse events. Given the fiscal and patient experience advantages of rapid-rate infusions, larger studies are needed to consider a change in practice.


Subject(s)
Biosimilar Pharmaceuticals , Inflammatory Bowel Diseases , Humans , Child , Infliximab/therapeutic use , Tumor Necrosis Factor Inhibitors , Biosimilar Pharmaceuticals/adverse effects , Antibodies, Monoclonal/therapeutic use , Gastrointestinal Agents/adverse effects , Treatment Outcome , Inflammatory Bowel Diseases/drug therapy
3.
Am J Health Syst Pharm ; 76(13): 992-997, 2019 Jun 18.
Article in English | MEDLINE | ID: mdl-31415686

ABSTRACT

PURPOSE: To describe the methods used in the development of an intravenous chemotherapy workload and productivity dashboard and its impact on symptoms of burnout and technician turnover. SUMMARY: In February 2017, chemotherapy sterile preparation pharmacy technicians reported symptoms of burnout as a result of perceived increase in workload. In response, an i.v. chemotherapy workload and productivity dashboard was developed at an academic medical center to validate workload in comparison to the reported job stress of pharmacy technicians. The dashboard provided pharmacy leadership objective data to validate staff concerns and leveraged lean principles to level-load the work prior to requesting additional full-time equivalents (FTEs) to senior leadership. The rate of turnover of i.v. chemotherapy technicians was assessed before (December 2016-June 2017) and after (July 2017-January 2018) dashboard implementation and approval of an additional i.v. chemotherapy technician FTE. The addition of the new FTE resulted in a decrease in productivity from an average of 106% (range 67%-151%) to 84% (range 65%-110%). The interventions allowed for the ability to leverage a staffing-to-demand model, resulting in the observed improvement in technician symptoms of burnout and a notable decrease in the overall turnover rate of i.v. chemotherapy technicians. CONCLUSION: The i.v. chemotherapy workload and productivity dashboard confirmed frontline staff perception and provided data to support the addition of labor resource and an opportunity to leverage a staffing-to-demand model to decrease symptoms of burnout and technician turnover.


Subject(s)
Efficiency, Organizational , Personnel Turnover/statistics & numerical data , Pharmacy Service, Hospital/organization & administration , Pharmacy Technicians/statistics & numerical data , Workload/statistics & numerical data , Administration, Intravenous , Antineoplastic Agents/administration & dosage , Attitude of Health Personnel , Burnout, Professional/epidemiology , Burnout, Professional/prevention & control , Burnout, Professional/psychology , Health Plan Implementation , Humans , Neoplasms/drug therapy , Pharmacy Service, Hospital/statistics & numerical data , Pharmacy Technicians/psychology , Program Development , Program Evaluation , Workload/psychology
4.
Cytometry A ; 73(10): 904-17, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18698634

ABSTRACT

High-content microscopic screening systems are powerful tools for extracting quantitative multiparameter measures from large number of cells under numerous conditions. These systems perform well in applications that monitor the presence of objects, but lack in their ability to accurately estimate object intensities and summarize these findings due to variations in background, aberrations in illumination, and variability in staining over the image and/or sample wells. We present effective and automated methods that are applicable to analyzing intensity-based cell cycle assays under high-throughput screening conditions. We characterize the system aberration response from images of calibration beads and then enhance the detection and segmentation accuracy of traditional algorithms by preprocessing images for local background variations. We also provide a rapid, adaptive, cell-cycle partitioning algorithm to characterize each sample well based on the estimated locally and globally corrected cell intensity measures of BrdU and DAPI incorporation. We demonstrated the utility and range of our cell ploidy and probe density measurement methods in a pilot screen using a siRNA library against 779 human protein kinases. With our method, multiple image-based quantitative phenotypes can be realized from a single high-throughput image-based microtiter-plate screen.


Subject(s)
Cell Cycle , Flow Cytometry , Image Processing, Computer-Assisted/standards , Protein Kinases/genetics , RNA, Small Interfering/genetics , Algorithms , Bromodeoxyuridine/analysis , Bromodeoxyuridine/metabolism , Calibration , Cell Line, Tumor , Cell Separation , Gene Silencing , Humans , Indoles/analysis , Indoles/metabolism , Staining and Labeling
SELECTION OF CITATIONS
SEARCH DETAIL
...